Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Bioject

This article was originally published in The Gray Sheet

Executive Summary

Bioject: Raises $3.3 mil. in gross proceeds in a private placement of approximately 2 mil. shares of common stock and five-year warrants to buy 1.5 mil. shares at $3 each. The company, which develops "jet" injection systems for needle-free drug delivery, currently markets the Biojector 2000 injection management system. Bioject also is developing a "personal injector system for self administration of beta interferon by multiple sclerosis patients in collaboration with Schering AG," and is working on an injector system for use with Hoffman-La Roche products. The firm says that the funding is "a key part" of its "overall financing strategy and an indication of the investors' confidence in Bioject's strategic vision"...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel